Education

• 1989-1995: Mie University, School of Medicine, M.D., Mie, Japan
• 1998-2002: Mie University Graduate School of Medicine, Ph.D., Mie, Japan

Professional Experiences

• 2002-2003: Fellow, Department of Hematology / Oncology, Mie University Hospital, Mie Japan
• 2003-2006: Research Fellow, Memorial Sloan Kettering Cancer Center, New York
• 2006-2010: Assistant Professor, Department of Cancer Vaccine, Mie University Graduate School of Medicine, Mie, Japan
• 2010-2015: Associate Professor, Experimental Immunology, IFReC,  Osaka University, Osaka, Japan
• 2012-2015: Adjunct Associate Professor, Department of Oncology, Roswell Park Cancer Institute, Buffalo, NY
• 2015~: Chief, Division of Cancer Immunology, Research Institute / Exploratory Oncology Research and Clinical Trial Center (EPOC), National Cancer Center
• 2016~: Professor and Chairperson, Department of Immunology, Nagoya University Graduate School of Medicine, Nagoya, Japan
• 2024~: Professor and Chairperson, Division of Cancer Immune Multicellular System Regulation, Center for Cancer Immunotherapy and Immunobiology (CCII), Kyoto University

Honors & Awards

• 2006 Incitement Award of the Japanese Cancer Association
• 2008 Cancer Research Institute, Investigator Award
• 2013 Cancer Research Institute, CLIP Award
• 2017 JCA (Japanese Cancer Association)-Mauvernay Award
• 2020 Society for Immunotherapy of Cancer (SITC), Team Science Award
• 2020 American Association for the Advancement of Science (AAAS), Elected Fellow
• 2022 The Commendation for Science and Technology by the Minister of Education, Culture, Sports, Science and Technology
• 2022 JCA (Japanese Cancer Association) Nagayama Award
• 2022 JSI (Japanese Society of Immunology) Human Immunology Research Award
• 2022 The Yasuda Medical Award
• 2023 Princess Takamatsu Cancer Research Fund Prize
• 2023 Kobayashi Foundation Cancer Science Award
• 2023 SGH Special Award
• 2023 Uehara Prize

• 2020, 2021, 2022, 2023 Highly Cited Researcher (Web of science, Clarivate^TM)

Memberships

• Japanese Society of Internal Medicine; Active member, 1995-present
• Japanese Cancer Association; Active member, 2000-present; Board Council, 2023-present
• Japanese Society of Immunology; Active member, 2000-present; Board Council, 2012-present
• Japanese Society of Cancer Immunology; Active member, 2000-present; Board Council, 2009-present
• American Association for Cancer Research (AACR); Active member, 2008-present
• American Society of Clinical Oncology (ASCO); Full member, 2015-present
• Society for Immunotherapy of Cancer (SITC); Active member, 2014-present

Member of Editorial Boards

• 2022~: Scientific Advisory Board, Science Translational Medicine
• 2022~: Senior Editor, Cancer Immunology Research (AACR official Journal)
• 2017~: Associate Editor, International Immunology (JSI official Journal)
• 2016~: Associate Editor, Cancer Science (JCA official Journal)
• 2013~: Academic Editor, PLOS One

Selected Publications

Original Articles

1. Itahashi K, IrieT, Yuda J, Kumagai S, Tanegashima T, Lin Y-Z, Watanabe S, Goto Y, Suzuki J, Aokage K, Tsuboi M, Minami Y, Ishii G, Ohe Y, Ise W, Kurosaki T, Suzuki Y, Koyama S, and Nishikawa H: BATF epigenetically and transcriptionally controls the activation program of regulatory T cells in human tumors. Sci Immunol. 14;7(76):eabk0957 2022.

2. Kumagai S, Koyama S, Itahashi K, Tanegashima T, Lin, Y-T, Togashi Y, Kamada T, Irie T, Okumura G, Kohno H, Ito D, Fujii R, Watanabe S, Sai A, Fukuoka S, Sugiyama E, Watanabe G, Owari T, Nishinakaumra H, Sugiyama D, Maeda Y, Kawazoe A, Yukami H, Cida K, Ohara Y, Yoshida T, Shinno Y, Takeyasu Y, Shirasawa M, Nakama K, Aokage K, Suzuki J, Ishii G, Kuwata T, Sakamoto N, Kawazu M, Ueno T, Mori T, Yamazaki N, Tsuboi M, Yatabe Y, Kinoshita T, Doi T, Shitara K, Mano H, and Nishikawa H: Lactic acid promotes PD-1 expression in regulatory T cells in highly glycolytic tumor microenvironments. Cancer Cell. Jan 25:S1535-6108(22)00003-4 2022. DOI: https://doi.org/10.1016/j.ccell.2022.01.001

3. Maeda Y, Wada H, Sugiyama D, Saito T, Irie T, Itahashi K, Minoura K, Suzuki S, Kojima T, Kakimi K, Nakajima J, Funakoshi T, Iida S, Oka M, Shimamura T, Doi T, Doki Y, Nakayama E, Ueda R, and Nishikawa H: Depletion of central memory CD8 ⁺ T cells might impede the antitumor therapeutic effect of Mogamulizumab. Nat Commun. 12(1):7280 2021. DOI: 10.1038/s41467-021-27574-0

4. Takeuchi Y, Tanegashima T, Sato E, Irie T, Sai A, Itahashi K, Kumagai S, Tada Y, Togashi Y, Koyama S, Akbay E.A, Karasaki T, Kataoka K, Funaki S, Shintani Y, Nagatomo I, Kida H, Ishii G, Miyoshi T, Aokage K, Kakimi K, Ogawa S, Okumura M, Eto M, Kumanogoh A, Tsuboi M, and Nishikawa H: Highly immunogenic cancer cells require activation of the WNT pathway for immunological escape. Sci Immunol.6(65):eabc6424 2021. DOI: https://doi.org/10.1126/sciimmunol.abc6424

5. Kumagai S, TogashiY, Kamada T, Sugiyama E, Nishinakaumra H, Takeuchi Y, Kochin, V, Itahashi K, Maeda Y, Matsui S, Shibahara,T, Yamashita Y, Irie T, Tsuge A, Fukuoka S, Kawazoe A, Udagawa H, Kirita K, Aokage K, Ishii G, Kuwata T, Nakama K, KawazuM, UenoT, Yamazaki N, Goto K, Tsuboi M, Mano H, Doi T, Shitara K, and Nishikawa H: The PD-1expression balance between effector and regulatory T cell predicts the clinical efficacy of PD-1 blockade therapies. Nat Immunol.21(11):1346-1358 2020.

6. Kumagai S, Togashi Y, Sakai C, Kawazoe A, Kawazu M, Ueno T, Sato E, Kuwata T, Kinoshita T, Yamamoto M, Nomura S, Tsukamoto T, Mano H, Shitara K, and Nishikawa H: An oncogenic alteration creates a tumor microenvironment that promotes tumor progression by conferring a metabolic advantage to regulatory T cells. Immunity. 53(1):187-203.e8 2020. DOI: 10.1016/j.immuni.2020.06.016

7. Sugiyama E, Togashi Y, Takeuchi Y, Shinya S, Tada Y, Kataoka K, Tane K, Sato E, Ishii G, Goto K, Shintani Y, Okumura M, Tsuboi M, and Nishikawa H:Blockade of EGFR improves responsiveness to PD1 blockade in EGFR-mutated non-small cell lung cancer. Sci Immunol. 5 (43). pii: eaav3937 2020. DOI: https://doi.org/10.1126/sciimmunol.aav3937

8. Tokunaga A, Sugiyama D, Maeda Y, Warner AB, Panageas KS, Ito S, Togashi Y, Sakai C, Wolchok JD, and Nishikawa H: Selective inhibition of low-affinity memory CD8⁺ T cells by corticosteroids. J Exp Med. 216(12):2701-2713 2019. DOI: 10.1084/jem.20190738

9. Saito T, Nishikawa H (Co-Corresponding author), Wada H, Nagano Y, Sugiyama D, Atarashi K, Maeda Y, Hamaguchi M, Ohkura N, Sato E, Nagase H, Nishimura J, Yamamoto H, Takiguchi S, Tanoue T, Suda W, Morita H, Hattori M, Honda K, Mori M, Doki Y, Sakaguchi S: Two FOXP3⁺CD4⁺ T-cell subpopulations distinctly control the prognosis of colorectal cancers. Nat Med. 22 (6):679-684 2016. DOI: 10.1038/nm.4086

10. Maeda Y, Nishikawa H (Co-corresponding author), Sugiyama D, Ha D, Hamaguchi M, Saito T, Nishioka M, Wing JB, Adeegbe D, Katayama I, Sakaguchi S: Detection of self-reactive CD8⁺T cells with an anergic phenotype in healthy individuals. Science. 346(6216):1536-1540 2014. DOI: 10.1126/science.aaa1292

Review Articles

1. Kumagai S, Itahashi K, and Nishikawa H: Regulatory T cell-mediated immunosuppression orchestrated by cancer: towards an immuno‑genomic paradigm for precision medicine. Nat Rev Clin Oncol. 21(5):337-353 2024. DOI: 10.1038/s41571-024-00870-6

2. Itahashi K, Irie T, and Nishikawa H: Regulatory T-cell development in the tumor microenvironment. Eur J Immunol. 52(8):1216-1227 2022. DOI: 10.1002/eji.202149358

3. Kumagai S, Koyama S, and Nishikawa H: Antitumour immunity regulated by aberrant ERBB family signalling. Nat Rev Cancer. 21(3):181-197 2021. DOI: 10.1038/s41568-020-00322-0

4. Koyama S, Nishikawa H: Mechanisms of regulatory T cell infiltration in tumors: implications for innovative immune precision therapies. J Immunother Cancer. 9(7):e002591 2021. DOI: 10.1136/jitc-2021-002591

5. Togashi Y, Shitara K, and Nishikawa H: Regulatory T cells in cancer immunosuppression – Implications for anticancer therapy. Nat Rev Clin Oncol.16(6):356-371 2019. DOI: 10.1038/s41571-019-0175-7